BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
1-Year Est. Return
11.48%
1 Year Est. Return
+11.48%
AUM
$656M
AUM Growth
+$43.2M
(+7%)
Holding
140
Top Buys
| 1 | +$8.17M | |
| 2 | +$5.64M | |
| 3 | +$4.88M | |
| 4 |
Eagle Bancorp
EGBN
|
+$4.88M |
| 5 |
LCI
Lannett Company, Inc.
LCI
|
+$4.31M |
Top Sells
| 1 | +$13.6M | |
| 2 | +$8.31M | |
| 3 | +$6.5M | |
| 4 |
Abbott
ABT
|
+$3.66M |
| 5 |
Tenet Healthcare
THC
|
+$3.53M |
Sector Composition
| 1 | Healthcare | 93.1% |
| 2 | Financials | 1.62% |
| 3 | Industrials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $26M | 3.97% |
217,410
-12,350
|
|
||
2
Biogen
BIIB
$22.6B
| $25.7M | 3.92% |
84,030
+12,260
|
|
||
3
Gilead Sciences
GILD
$149B
| $24.3M | 3.7% |
240,120
-13,930
|
|
||
4
Amgen
AMGN
$161B
| $20M | 3.04% |
123,000
+3,000
|
|
||
5
Regeneron Pharmaceuticals
REGN
$68.5B
| $19.8M | 3.01% |
36,400
-2,500
|
|
||
6
Medtronic
MDT
$116B
| $19.7M | 3.01% |
256,500
-13,500
|
|
||
7
Illumina
ILMN
$19B
| $17.5M | 2.67% |
93,985
+3,906
|
|
||
|
8
Abbott
ABT
$215B
| $17.1M | 2.61% |
381,500
-81,500
|
|
||
9
Viatris
VTRS
$12B
| $17M | 2.6% |
315,300
+90,300
|
|
||
10
Becton Dickinson
BDX
$51.2B
| $16.2M | 2.47% |
107,702
+13,089
|
|
||
11
Cardinal Health
CAH
$45.3B
| $15.3M | 2.33% |
171,480
+91,480
|
|
||
12
UnitedHealth
UNH
$309B
| $14.1M | 2.15% |
120,000
|
|
||
13
Stryker
SYK
$136B
| $13.1M | 1.99% |
140,700
|
|
||
14
Teva Pharmaceuticals
TEVA
$23.5B
| $11.6M | 1.77% |
176,720
+7,500
|
|
||
|
ESRX
15
DELISTED
Express Scripts Holding Company
ESRX
| $10.8M | 1.65% |
124,000
-36,000
|
|
||
|
ENDP
16
DELISTED
Endo International plc
ENDP
| $10.5M | 1.6% |
171,000
+13,000
|
|
||
|
CYTO
17
DELISTED
Altamira Therapeutics Ltd
CYTO
| $10.4M | 1.59% |
27
|
|
||
18
Zimmer Biomet
ZBH
$19.9B
| $9.8M | 1.49% |
98,365
|
|
||
|
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.42M | 1.44% |
49,400
|
|
||
20
CVS Health
CVS
$99.2B
| $9.4M | 1.43% |
96,200
+41,200
|
|
||
21
Ligand Pharmaceuticals
LGND
$3.73B
| $8.85M | 1.35% |
130,869
-22,586
|
|
||
22
Incyte
INCY
$18.4B
| $8.57M | 1.31% |
79,000
+2,000
|
|
||
23
Ionis Pharmaceuticals
IONS
$12B
| $8.55M | 1.3% |
138,000
+6,000
|
|
||
24
Boston Scientific
BSX
$149B
| $8.48M | 1.29% |
460,000
+60,000
|
|
||
25
McKesson
MCK
$101B
| $8.48M | 1.29% |
43,000
+2,000
|
|